Fiore RX Antifungal Nail Lacquer Claims Clipped At NAD After Avoiding FTC
This article was originally published in The Tan Sheet
Executive Summary
NAD welcomes Fiore RX back to the self-regulatory process a year after referring its Fiore Rx Antifungal Nail Lacquer claims to FTC. The review does not go favorably for the firm, which must discontinue or modify all 22 claims NAD targeted for lack of substantiating evidence.